Long-Term Protective Effect of Tuberculosis Preventive Therapy in a Medium/High Tuberculosis Incidence Setting
Clinical Infectious Diseases · 2024
DOI: 10.1093/cid/ciae101 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Leidy Anne Alves Teixeira und 6 weiteren Autor:innen. Beteiligte Einrichtung: Instituto Nacional de Cardiologia, Núcleo de Avaliação de Tecnologias em Saúde, Rio de Janeiro, Brazil. Hauptthemen laut MEDLINE: Tuberculosis, Antitubercular Agents, Isoniazid, HIV Infections. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Background
The duration of the protective effect of tuberculosis preventive therapy (TPT) is controversial. Some studies have found that the protective effect of TPT is lost after cessation of therapy among people with human immunodeficiency virus (HIV) in settings with very high tuberculosis incidence, but others have found long-term protection in low-incidence settings.
Methods
We estimated the incidence rate (IR) of new tuberculosis disease for up to 12 years after randomization to 4 months of rifampin or 9 months of isoniazid, among 991 Brazilian participants in a TPT trial in the state of Rio de Janeiro, with an incidence of 68.6/100 000 population in 2022. The adjusted hazard ratios (aHRs) of independent variables for incident tuberculosis were calculated.
Results
The overall tuberculosis IR was 1.7 (95% confidence interval [CI], 1.01– 2.7) per 1000 person-years (PY). The tuberculosis IR was higher among those who did not complete TPT than in those who did (2.9 [95% CI, 1.3–5.6] vs 1.1 [.4–2.3] per 1000 PY; IR ratio, 2.7 [1.0–7.2]). The tuberculosis IR was higher within 28 months after randomization (IR, 3.5 [95% CI, 1.6–6.6] vs 1.1 [.5–2.1] per 1000 PY between 28 and 143 months; IR ratio, 3.1 [1.2–8.2]). Treatment noncompletion was the only variable associated with incident tuberculosis (aHR, 3.2 [95% CI, 1.1–9.7]).
Conclusions
In a mostly HIV-noninfected population, a complete course of TPT conferred long-term protection against tuberculosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Instituto Nacional de Cardiologia, Núcleo de Avaliação de Tecnologias em Saúde, Rio de Janeiro, Brazil.
- McGill International Tuberculosis Centre, Research Institute of the McGill University Health Centre, and McGill University, Montreal, Quebec, Canada.
- Family Medicine Department, University of Manitoba, Winnipeg, Manitoba, Canada.
- Universidade Federal do Rio de Janeiro Departamento de Clínica Médica, Rio de Janeiro, Brazil.
- McGill International Tuberculosis Centre, McGill University, Montreal, Quebec, Canada.
ORCID-Profile: Leidy Anne Alves Teixeira, Anete Trajman
Zitieren
APA
Teixeira, L. A. A., Santos, B., Correia, M. G., Valiquette, C., Bastos, M. L., Menzies, D., & Trajman, A. (2024). Long-Term Protective Effect of Tuberculosis Preventive Therapy in a Medium/High Tuberculosis Incidence Setting. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae101
Vancouver
Teixeira LAA, Santos B, Correia MG, Valiquette C, Bastos ML, Menzies D, et al. Long-Term Protective Effect of Tuberculosis Preventive Therapy in a Medium/High Tuberculosis Incidence Setting. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciae101
BibTeX
@article{Teixeira2024,
author = {Teixeira, Leidy Anne Alves and Santos, Braulio and Correia, Marcelo Goulart and Valiquette, Chantal and Bastos, Mayara Lisboa and Menzies, Dick and Trajman, Anete},
title = {Long-Term Protective Effect of Tuberculosis Preventive Therapy in a Medium/High Tuberculosis Incidence Setting},
journal = {Clinical Infectious Diseases},
year = {2024},
doi = {10.1093/cid/ciae101}
}
EUVIMED